

Pfizer in Europe: Resilience and Innovation in Patient Supply



- We help provide medicines and vaccines to more than **600 million patients** in **over 180 countries**.
- Pfizer's ability to meet patient needs in Europe and around the globe depends on a **stable, pro-innovation policy environment** and the ability to maintain a **supply chain that is both flexible and resilient**.
- We operate one of the most sophisticated supply chain systems in the industry, with:
 - 35+ Pfizer-owned sites
 - 300+ suppliers globally
- Pfizer continues to make progress on our **Environmental, Social and Governance (ESG) strategy** and we aim to achieve the **voluntary net zero standard by 2040**.¹

With a presence here since the 1950's, Europe is home to:


OVER
14,000
COLLEAGUES

WORKING IN MANUFACTURING



16 MANUFACTURING, SUPPLY AND R&D SITES

OUR SITES HERE PRODUCE ACTIVE PHARMACEUTICAL INGREDIENTS (APIs) AND FINISHED MEDICINES, RANGING FROM SMALL MOLECULES, TO STERILE INJECTABLE HOSPITAL PRODUCTS, VACCINES AND BIOLOGICS.




PFIZER LOGISTICS CENTERS IN EUROPE MADE

908,000 SHIPMENTS

ANNUALLY TO CUSTOMERS ACROSS THE CONTINENT

OUR SITES IN EUROPE HANDLE

97% OF PFIZER MEDICINES SOLD HERE



OF THE APIs IN OUR PATENTED MEDICINES COME FROM EUROPE²

Pfizer has invested significantly in our workforce and operations across Europe.

This is driven by multiple imperatives, including:

- **Manufacturing scale-up** to respond to the COVID-19 pandemic.
- Ensuring **best-in-class logistics** to meet patient demand across Europe and globally.
- **Increasing production capacity and technical capabilities** for today's and tomorrow's medicines.
- Maintaining a **cutting edge in R&D and digital innovation**.
- Finding innovative ways to **minimise our impact on the environment**.

● Pfizer site
■ Pfizer Investments Across Europe since 2020

Biologics Production Capacity expansion, Grange Castle

Manufacturing and Laboratory Expansion, Ringaskiddy & Newbridge

Biologics Site Expansion, Strängnäs

Production, Packaging, Warehouse Capacity Expansion, Puurs

High-Con Facility, Freiburg

R&D, Digital, Venture Funding, Production, France

Gene Therapy Production and Distribution, San Sebastián de los Reyes

Center for Digital Innovation, Thessaloniki

New Biologics Production Facility, Zagreb

For more details on these examples, please visit:
<https://www.pfizer.eu/policy.eu/InvestedInEurope>

Leadership in Supply Resilience

Pfizer's robust global network and seamless operations are driven by the vital understanding that patients can't afford any delays or disruptions in getting the medicines and vaccines they need:



We use **multiple suppliers** to minimise risk of supply interruptions of essential medicines.



We've established **parallel supply chains** throughout the U.S. and Europe to manufacture our most critical vaccines.



Our supply chain has **built-in flexibility** to support resiliency, extra inventory, an increased workforce, and multiple suppliers.



We aim to ensure that all Pfizer medicines and vaccines are made to **our standards of quality, efficacy, and safety.**



If a shortage does occur, **we work closely with authorities** to minimise patient impact and mitigate it as fast as possible.

During the first wave of the pandemic in 2020, Pfizer implemented an unprecedented plan to **meet demand spikes of >200% for our medicines in Europe**, particularly for intensive care units (ICU).

To date (January 2024), Pfizer and BioNTech have shipped **more than 4.9 billion Covid-19 vaccines to 183 countries and territories** around the world.

In June 2023, Pfizer entered into an agreement with the European Commission to reserve **EU-based manufacturing capacity for mRNA vaccines** in case of a future public health emergency.ⁱⁱⁱ

Policy Recommendations

↔ Facilitate Trade

- Trade barriers such as export restrictions add uncertainty, cost, and delay to patient access.
- This can be avoided by removing barriers on medical goods and improving efficiency of customs procedures.



Foster resilient supply chains

- Mandatory local sourcing can limit companies' ability to deliver medicines in the most effective manner.
- Policies that enable a favourable ecosystem for investment in innovation will also support the resilience of supply.



Enable Innovation

- Intellectual Property (IP) is the key driver of medical innovation.
- Fostering an R&D ecosystem to deliver that innovation is the best way to protect patients in Europe and globally.



Optimise Use of Data and Dialogue

- Responding to changing supply needs can benefit from greater access to real-time data.
- Prompt government-industry dialogue can help enable efficient and appropriate reactions to changing conditions.



Strategically Manage Inventory

- Stockpiling can create distortions that inhibit demand forecasting and the ability to build excess capacity.
- As well as being risk-based and proportionate, policies should ensure that demand represents true patient need and enable flexible allocation of inventory.



Strengthen Regulatory Cooperation

- The pandemic showed that companies and regulators can collaborate to fast-track lifesaving medicine approvals, without jeopardising safety.
- Cooperation, best practice sharing, and capacity-building should be expanded.

This information is intended to support policy discussions with policy stakeholders. Information correct as of February 2024.

ⁱ For more information on ESG, please see: https://www.pfizerupolicy.eu/sites/default/files/Pfizer_ESG-Commitment_Infographic_FINAL_0.pdf

ⁱⁱ Statistics on customer shipments do not include UK. API sourcing statistics: 76% from Europe, 19% from the US and 5% from Asia.

ⁱⁱⁱ https://hadea.ec.europa.eu/system/files/2023-06/230531_EUfab-call_v01_0.pdf